Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations

• US 8,409,612 B1
• Filed: 05/19/2000
• Issued: 04/02/2013
• Est. Priority Date: 05/21/1999
• Status: Expired due to Fees

• Current Assignee: Laboratoires des produits Ethiques Ethypharm SA
• Original Assignee: ETHYPHARM
• Inventors: Criere, Bruno, Suplie, Pascal, Oury, Pascal
• Primary Examiner(s): CHANNAVAJJALA, LAKSHMI SARADA
• Application Number:
  US09/979,146
• Time in Patent Office: 4,701 Days
• Field of Search: 424/451, 424/464, 424/489, 424/490, 424/497, 424/498
• US Class Current: 424/464
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical formulation of a gastric proton pump inhibitor, with the exception of omeprazole, is disclosed. The formulation is in the form of microgranules insoluble in gastric fluid having improved stability over time. The formulation comprises several hydrophobic substances chosen in order to increase the stability of the active principle while obtaining the desired dissolution profile.

Claims

1. A microgranule comprising a gastric proton pump inhibitor, with the exception of omeprazole, comprising an active layer comprising the proton pump inhibitor and an outer layer for protection in gastric fluid, wherein:

(A) the active layer is applied to a neutral nucleus;

(B) the active layer comprises at least one hydrophobic substance chosen from silicone oils and present in the active layer in an amount of between 5 and 40% by weight of the gastric proton pump inhibitor;

(C) and the layer for protection in gastric fluid comprises at least one hydrophobic substance chosen from glycerides and present in the layer for protection in gastric fluid in an amount of 5 to 20% by weight of the protective layer; and

further wherein the microgranule has no alkaline compound and no ionic surfactant.

2. The microgranule as claimed in claim 1, wherein the active layer comprises 5 to 15%, with respect to the weight of proton pump inhibitor, of a nonionic surfactant.

3. The microgranule as claimed in claim 1, wherein the active layer further comprises a binder.

4. The microgranule as claimed in claim 1, wherein the layer for protection in gastric fluid is composed of 90 to 95% of film-forming agent and of 5 to 10% of an equal amount of plasticizer and of hydrophobic substance.

5. The microgranule as claimed in claim 4, wherein the plasticizer represents 5 to 20% by weight of the dry glaze of the film-forming agent.

6. The microgranule as claimed in claim 4, wherein the film-forming agent is from 15 to 60% of the dry polymer deposit with respect to the mass of the microgranule.

7. The microgranule as claimed in claim 4, wherein the film-forming agent is a copolymer of methacrylic acid.

8. The microgranule as claimed in claim 1, which further comprises at least one intermediate layer inserted between the active layer and the layer for protection in gastric fluid.

9. The microgranule as claimed in claim 8, wherein each microgranule comprises:

(a) an active layer comprising a proton pump inhibitor, a binder chosen from pharmaceutically acceptable binders, a hydrophobic substance and a nonionic surfactant,

(b) a first protective layer comprising one or more pharmaceutically acceptable hydrophobic diluent substances and a binder,

(c) a second hydrophobic protective layer comprising a coating agent and a hydrophobic plasticizer, and

(d) a layer for protection in gastric fluid comprising an enteric film-forming agent, a hydrophilic plasticizer and a hydrophobic substance.

10. The microgranule as claimed in claim 9, wherein the first protective layer comprises mannitol as a diluent substance.

11. The microgranule as claimed in claim 9, wherein the second protective layer is composed of a water-soluble coating agent and of a hydrophobic plasticizer.

12. The microgranule as claimed in claim 1, wherein the active layer is applied to a neutral nucleus and the particle size of the microgranule is between 0.3 and 3 mm.

13. The microgranule as claimed in claim 1, wherein the microgranule comprises:

35 to 45% of neutral nucleus, 15 to 25% of mannitol, 5 to 15% of proton pump inhibitor, 8 to 15% of hydroxypropylmethylcellulose, 15 to 60% of a copolymer of methacrylic acid, 0.5 to 1.5% of a silicone oil, 0.5 to 1.5% of a nonionic surfactant, 1 to 6% of a plasticizer, 1 to 6% of a glyceride, and 1 to 2% of talc, wherein said percentages are expressed by mass.

14. A process for the preparation of the microgranule as claimed in claim 1, wherein said microgranule is prepared in an aqueous medium.

15. A process as claimed in claim 14, wherein the active layer is applied to a neutral nucleus in a fluidized air bed.

16. A pharmaceutical preparation comprising the microgranule as claimed in claim 1, comprising approximately 5 to 60 mg of proton pump inhibitor and a pharmaceutically acceptable carrier.

17. The microgranule as claimed in claim 2, wherein the nonionic surfactant is a polysorbate.

18. The microgranule as claimed in claim 3, wherein the binder is hydroxypropylmethylcellulose.

19. The microgranule as claimed in claim 11, wherein the water-soluble coating agent is hydroxypropylmethylcellulose.

20. The microgranule as claimed in claim 11, wherein the hydrophobic plasticizer is an acetylated monoglyceride.

21. The microgranule as claimed in claim 1, wherein said neutral nucleus has a diameter between 200 microns and 900 microns.

22. A microgranule comprising a gastric proton pump inhibitor, with the exception of omeprazole, comprising an active layer comprising the proton pump inhibitor and an outer layer for protection in gastric fluid, wherein:

(A) the active layer is applied to a single neutral nucleus;

(B) the active layer comprises at least one hydrophobic substance chosen from silicone oils and present in the active layer in an amount of between 5 and 40% by weight of the gastric proton pump inhibitor;

(C) and the layer for protection in gastric fluid comprises at least one hydrophobic substance chosen from glycerides and present in the layer for protection in gastric fluid in an amount of 5 to 20% by weight of the protective layer;

and further wherein the microgranule has no alkaline compound and no ionic surfactant.